159 related articles for article (PubMed ID: 17227236)
1. Is YKL-40 a new therapeutic target in cancer?
Johansen JS; Jensen BV; Roslind A; Price PA
Expert Opin Ther Targets; 2007 Feb; 11(2):219-34. PubMed ID: 17227236
[TBL] [Abstract][Full Text] [Related]
2. Serum YKL-40, a new prognostic biomarker in cancer patients?
Johansen JS; Jensen BV; Roslind A; Nielsen D; Price PA
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):194-202. PubMed ID: 16492905
[TBL] [Abstract][Full Text] [Related]
3. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Jensen BV; Johansen JS; Price PA
Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
[TBL] [Abstract][Full Text] [Related]
4. Plasma YKL-40: a potential new cancer biomarker?
Johansen JS; Schultz NA; Jensen BV
Future Oncol; 2009 Sep; 5(7):1065-82. PubMed ID: 19792974
[TBL] [Abstract][Full Text] [Related]
5. [The importance of determining the prognostic marker YKL-40 in serum and tissues].
Łata E; Gisterek I; Matkowski R; Szelachowska J; Kornafel J
Pol Merkur Lekarski; 2010 Jun; 28(168):505-8. PubMed ID: 20642115
[TBL] [Abstract][Full Text] [Related]
6. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
[TBL] [Abstract][Full Text] [Related]
8. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C
Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741
[TBL] [Abstract][Full Text] [Related]
9. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.
Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
Cancer; 2002 Jul; 95(2):267-74. PubMed ID: 12124825
[TBL] [Abstract][Full Text] [Related]
10. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
[TBL] [Abstract][Full Text] [Related]
11. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer.
Johansen JS; Cintin C; Jørgensen M; Kamby C; Price PA
Eur J Cancer; 1995; 31A(9):1437-42. PubMed ID: 7577068
[TBL] [Abstract][Full Text] [Related]
12. Serum YKL-40 and colorectal cancer.
Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
Br J Cancer; 1999 Mar; 79(9-10):1494-9. PubMed ID: 10188896
[TBL] [Abstract][Full Text] [Related]
13. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
[TBL] [Abstract][Full Text] [Related]
14. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
Dehn H; Høgdall EV; Johansen JS; Jørgensen M; Price PA; Engelholm SA; Høgdall CK
Acta Obstet Gynecol Scand; 2003 Mar; 82(3):287-93. PubMed ID: 12694127
[TBL] [Abstract][Full Text] [Related]
15. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
[TBL] [Abstract][Full Text] [Related]
16. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
[TBL] [Abstract][Full Text] [Related]
17. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
[TBL] [Abstract][Full Text] [Related]
19. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects.
Johansen JS; Lottenburger T; Nielsen HJ; Jensen JE; Svendsen MN; Kollerup G; Christensen IJ
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2603-8. PubMed ID: 18843001
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.
Kim SH; Das K; Noreen S; Coffman F; Hameed M
World J Surg Oncol; 2007 Feb; 5():17. PubMed ID: 17286869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
